Trial Profile
A Safety and Feasibility Trial of Boost Vaccinations of a Lethally Irradiated, Allogeneic Pancreatic Tumor Cell Vaccine Transfected With the GM-CSF Gene
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Cyclophosphamide (Primary) ; Tumour cell vaccine-GVAX (Primary)
- Indications Adenocarcinoma; Head and neck cancer; Pancreatic cancer
- Focus Therapeutic Use
- 30 Oct 2023 Planned End Date changed from 1 Aug 2023 to 1 Aug 2024.
- 30 Oct 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Aug 2024.
- 06 Mar 2023 Planned End Date changed from 1 Apr 2023 to 1 Aug 2023.